BGB-11417 (WM): A phase 2 trial of BGB-11417 in people with relapsed or refractory Waldenstrom’s Macroglobulinaemia

This trial is testing the medication BGB-11417 in people with Waldenstrom’s Macroglobulinaemia (WM) which has come back after (relapsed), or not responded (refractory) to treatment.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05952037

Trial aim and background  

The aim of this trial is to find out how safe and effective the BCL-2 inhibitor BGB-11417 is when given to patients with WM which has relapsed, or is refractory to current treatment options. 

The main goals are to see how many participants go into remission following the treatment, how many have an improvement in signs and symptoms, and finally if there are any side effects. 

BGB-11417 is a BCL-2 inhibitor. BCL-2 is a protein produced by some lymphoma cells which keeps them alive longer. BCL-2 inhibitors block this protein.

Who can enter 

People with relapsed or refractory WM may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • Churchill Hospital, Oxford University Hospital NHS Trust, Headington
  • Beatson West of Scotland Cancer Centre, Glasgow
  • University Hospitals Dorset, Bournemouth
  • University College London Hospitals, London
  • The Christie, Manchester
  • Inverness, Scotland

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05952037

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.